



NON-EXECUTIVE DIRECTOR APPOINTMENT

26 June 2026, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Meghan Rivera has accepted an invitation to join the Board of Mayne Pharma, effective 26 June 2026. Ms Rivera's appointment follows the recruitment process announced in April 2026.

Ms Rivera, a US resident, has more than 25 years of experience in the US pharmaceutical industry. She is currently Vice President and Global Commercial Lead for ViiV Healthcare, a leading biopharmaceutical organization focused on prevention, treatment, and cure of HIV.

Previously, Ms Rivera served as US Market President at Organon & Co (NYSE:OGN), where she oversaw five diverse business units spanning women's health, fertility, medtech, biosimilars, and established brands, delivering more than \$1.6 billion in revenue. Prior to her role at Organon, she was Chief Marketing Officer and Head of Commercial at Akili Interactive and Senior Vice President of Women's Health at AMAG Pharmaceuticals.

Mayne Pharma's Chair Professor Bruce Robinson said, *"We are delighted to welcome Meghan to the Board of Mayne Pharma. She is an experienced executive with a wealth of US pharma experience. Meghan has extensive experience in building, scaling, and transforming businesses across biopharma and played a key role in launching branded products in the US. Her experience spans multiple therapeutic areas including women's health."*

Commenting on her appointment, Ms Rivera said, *"I look forward to joining the Board of Mayne Pharma and helping to unlock the full commercial potential of the Company. Having spent my career building high-performing US pharma organisations, I recognise the quality of what Mayne has assembled with a differentiated portfolio spanning Women's Health and Dermatology, and a proprietary direct-to-patient distribution platform in DistributeRx that has strong strategic merit and genuine competitive advantages. I look forward to contributing to the next chapter of growth for Mayne Pharma and its shareholders."*

Ms Rivera holds a Bachelor of Science, Business Administration from the University of Atlanta and a corporate finance certification from Columbia University.

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board of Directors.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia





ASX Announcement

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

